Immunosuppressive treatment groups
| Immunosuppression treatment . | No. of patients in treatment group for whom data were known (%) . |
|---|---|
| Steroids alone | 40 (26.49) |
| Concomitant steroids and cytotoxics | 48 (31.79) |
| Cytotoxics added after initial treatment with steroids alone | 13 (8.61) |
| Order of steroids and cytotoxics unknown | 31 (20.53) |
| Cytotoxics alone | 8 (5.30) |
| No treatment | 8 (95.30) |
| Other regimen | 3 (1.99) |
| Immunosuppression treatment . | No. of patients in treatment group for whom data were known (%) . |
|---|---|
| Steroids alone | 40 (26.49) |
| Concomitant steroids and cytotoxics | 48 (31.79) |
| Cytotoxics added after initial treatment with steroids alone | 13 (8.61) |
| Order of steroids and cytotoxics unknown | 31 (20.53) |
| Cytotoxics alone | 8 (5.30) |
| No treatment | 8 (95.30) |
| Other regimen | 3 (1.99) |
Total number of patients in treatment group for whom data were known is 151. Patients were treated with immunosuppression at the discretion of the local clinician. The total number of patients and the percentage of the cohort receiving each treatment are shown. “Concomitant steroids and cytotoxics” means that these drugs were both started together at presentation. In the “Order of steroids and cytotoxics unknown” group, it is not known whether patients initially received steroids and cytotoxics were then added or these drugs were given together at presentation. In almost all cases steroids were prednisolone 1 mg/kg, and cytotoxics were cyclophosphamide 1 to 2 mg/kg body weight. Other regimens included the use of cyclosporine A and rituximab.